Amneal Pharmaceuticals (AMRX) Enterprise Value (2017 - 2026)

Amneal Pharmaceuticals' Enterprise Value history runs 10 years deep, the most recent figure standing at -$4.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 107.17% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$4.7 million (down 107.17% YoY), while the FY2025 annual figure was -$282.6 million, down 595.08% from the prior year.
• Enterprise Value was -$4.7 million for Q1 2026 at Amneal Pharmaceuticals, up from -$282.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $66.0 million in Q1 2025 to a low of -$282.6 million in Q4 2025.
• Historically, Enterprise Value has averaged -$16.0 million across 5 years, with a median of $11.7 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 2172.82% in 2022, then jumped 3384.13% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$1.0 million in 2022, then surged by 3384.13% to $33.7 million in 2023, then jumped by 69.22% to $57.1 million in 2024, then sank by 595.08% to -$282.6 million in 2025, then jumped by 98.33% to -$4.7 million in 2026.
• The last three Enterprise Value figures came in at -$4.7 million (Q1 2026), -$282.6 million (Q4 2025), and $33.1 million (Q3 2025), per Business Quant data.